| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 536700100 | Oxygen containing hetero ring having 12-19 members (e.g., methymycin, carbomycin, spiramycin, etc.) | 34 |
| 20080300388 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative - A novel compound that has antimicrobial activity against penicillin-resistant | 12-04-2008 |
| 20090076253 | MACROLIDE DERIVATIVES - Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD). | 03-19-2009 |
| 20100081800 | MACROCYCLIC POLYMORPHS, COMPOSITIONS COMPRISING SUCH POLYMORPHS, AND METHODS OF USE AND MANUFACTURE THEREOF - The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to | 04-01-2010 |
| 20100113757 | NOVEL MACROLIDE ANTIBIOTICS AND THEIR USE FOR MEDICAL PURPOSES - The invention provides novel Thuggacin-Type macrolide compounds which form rearrangement products forming a lacton bond to different carbon atoms. The novel compounds can be produced by fermentation of | 05-06-2010 |
| 20100280230 | METHOD OF PREPARING CLARITHROMYCIN - This invention discloses a method of manufacturing clarithromycin, where an erythromycin A 9-oxime thiocyanate salt is used directly to perform an etherification reaction, and then successively silanizattion, methylattion and hydrolysis reactions are sequentially conducted. It is a new process with simple process with a high yield, low cost, less pollution, high quality and is suitable for commercial manufacturing. | 11-04-2010 |
| 20110040078 | PROCESS FOR THE PRODUCTION OF TELITHROMYCIN - The present invention relates to a process for the preparation of erythromysin derivatives, in particular telithromycin of formula (I) and its pharmaceutically acceptable salts, providing the isolated intermediates in crystalline form of superior stability and purity. | 02-17-2011 |
| 20110124850 | Glycorandomization and Production of Novel Vancomycin Analogs - The present invention provides glycorandomized structures and combinatorial methods for rapidly generating a diverse library of glycorandomized structures, comprising incubating one or more aglycons and a pool of NDP-sugars in the presence of a glycosyltransferase. The glycosyltransferase may be one that is associated with or involved in production of natural secondary metabolites, or one which is putatively associated with or involved in production of natural secondary metabolites. The glycosyltransferase may show significant flexibility with respect to its NDP-sugar donors and/or its aglycons. NDP-sugar donors may be commercially available, or may be produced by utilizing mutant or wild type nucleotidyltransferases significant flexibility with respect to their substrates. | 05-26-2011 |
| 20120035352 | 6-11 Bicyclic Ketolide Derivatives - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-09-2012 |
| 20130123477 | Tiacumicin Production - Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species | 05-16-2013 |
| 20130165641 | 6,11-BRIDGED BIARYL MACROLIDES - The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-27-2013 |
| 20130267692 | PROCEDURE FOR THE PURIFICATION OF TIACUMICIN B - The present invention relates to an improved process for the purification of tiacumicin B. Specifically, the invention relates to a simplified, optimised process for the purification of tiacumicin B from a fermentation broth, using chromatography techniques. In particular, the invention relates to a method for purifying tiacumicin B which comprises subjecting a liquid containing tiacumicin B to at least one hydrophobic interaction chromatography step. | 10-10-2013 |
| 20130274457 | METHOD FOR TRANSFORMING PHARMACEUTICAL CRYSTAL FORMS - The present invention provides gas-induced method for phase-transforming organic solids, such as pharmaceutical crystals. The inventive method subjects the polymorphs of pharmaceutical agents to various pressures of gases (such as CO | 10-17-2013 |
| 20130345410 | NOVEL ANTIBACTERIAL AGENTS - Described herein are novel macrolides, the preparation of novel macrolides, the use of novel macrolides for preventing, treating, or ameliorating various conditions, and the use of novel macrolides as antibacterial agents. | 12-26-2013 |
| 20140039171 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS - Provided are: a novel monoalkylamino intermediate (I); and a production method for a compound represented by the formula (III), which is an animal antibacterial agent, via the novel monoalkylamino intermediate. | 02-06-2014 |
| 20140073770 | Process for preparation of ketolide intermediates - The inventions discloses a process for preparation of compounds of Formula (IX), Wherein, R is C | 03-13-2014 |
| 20140135485 | 6-11 BICYCLIC KETOLIDE DERIVATIVES - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 05-15-2014 |
| 20140296498 | Tiacumicin Production - Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species | 10-02-2014 |
| 20150313929 | USE OF TYLVALOSIN AS ANTIVIRAL AGENT - The Invention relates to the use of antibiotic, tylvalosin, as an anti-viral agent. Tylvalosin is particularly useful for the treatment of PRRSV. | 11-05-2015 |
| 20150329581 | NEW SYNTHESIS PROCESS OF ANTIPARASITIC DRUG SELAMECTIN - Provided in the present invention are novel key intermediates of selamectin and the preparation method thereof. Also provided is a new synthesis process, using doramectin as a starting material, and obtaining selamectin via hydrogenation, oxidation, oximation and desugaring. The new process of the present invention has few steps, and is simple to operate, high in yield, low in cost and causes little pollution, and is more suitable for large scale industrial production. | 11-19-2015 |
| 20160046660 | CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS - The invention described herein relates to processes for preparing ketolide antibacterial agents. In particular, the invention relates to intermediates and processes for preparing ketolides that include a 1,2,3-triazole substituted side chain. | 02-18-2016 |
| 20160083764 | AN IMPROVED PROCESS FOR THE PREPARATION OF FIDAXOMICIN - The present invention provides an improved process for the preparation of fidaxomicin by culturing | 03-24-2016 |
| 536700200 | Erythromycin or derivative (e.g., oleandomycin, etc.) | 13 |
| 20080200659 | Combinatorial polyketide libraries produced using a modular PKS gene cluster as scaffold - Combinatorial libraries of polyketides can be obtained by suitable manipulation of a host modular polyketide synthase gene cluster such as that which encodes the PKS for erythromycin. The combinatorial library is useful as a source of pharmaceutically active compounds. In addition, novel polyketides and antibiotics are prepared using this method. | 08-21-2008 |
| 20090054634 | Process for the preparation of clarithromycin - The present invention includes a process involving a one-pot reaction for preparing erythromycin 9-oxime salt comprising: (a) reacting erythromycin thiocyanate with an ammonium source to obtain erythromycin free base; (b) oximating the C-9 carbonyl of the erythromycin free base by reacting the erythromycin free base with triethylamine and hydroxyl amine hydrochloride to form erythromycin oxime; and (c) reacting the erythromycin oxime obtained in step (b) with an ammonium source to obtain the erythromycin 9-oxime salt. The present invention is also drawn to a one-pot reaction for preparing clarithromycin starting with the one-pot reaction for preparing erythromycin 9-oxime salt, further comprising after step (c): (d) silylating the hydroxy groups at the oxime group, and the 2′ and 4″ positions of the erythromycin 9-oxime salt to obtain a silylated derivative; (e) methylating the hydroxy group at the 6 position of the silylated derivative using at least one methylating agent in the presence of at least one inorganic base to obtain SMOP, wherein SMOP is 6-O-methyl-2′,4″-bis(trimethylsilyl)-erythromycin A 9-O-(2-methoxyprop-2-yl)oxime; and (f) converting the SMOP into clarithromycin using at least one deoximating agent in the presence of aqueous ethanol. | 02-26-2009 |
| 20110172402 | CRYSTALLIZING METHOD OF ERYTHROMYCIN - The present invention provides an erythromycin crystallizing method, which comprises using dichloromethane containing solvent as a preparation solvent, and the dichloromethane solution of erythromycin received was gradiently cooled from high temperature down to low temperature, and thus making erythromycin crystallize. According to the method of the present invention, the content of erythromycin A is high, the content of erythromycin A in the erythromycin crystalline is more than 94.5% (HPLC detection method), the content of dichloromethane in the erythromycin crystalline is less than 600 ppm, the content of water in the erythromycin crystalline is less than 2.5%, the microbiological titre of the erythromycin crystalline is more than 940 μ/mg. | 07-14-2011 |
| 20140128583 | ERYTHROMYCIN ETHYLSUCCINATE CRYSTALLINE HYDRATE, PREPARATION AND USES THEREOF - Disclosed is an anti-infective drug-macrolide derivate, preparation and uses thereof. Macrolide derivate, namely erythromycin ethylsuccinate crystalline hydrate, which has less moisture absorption and good storage stability, can be used in the preparation of medicaments for the treatment and prevention of human or animal infectious diseases caused by Gram-positive or negative bacteria. | 05-08-2014 |
| 536700300 | Boron, phosphorus or sulfur containing | 1 |
| 20140046043 | C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE - A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas). | 02-13-2014 |
| 536700400 | Additional nitrogen containing | 8 |
| 20080262208 | 6-11 Bridged Oxime Erythromycin Derivatives - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-23-2008 |
| 20090281292 | 10a-Azalide Compound - [Object]: To provide a compound having a novel structure effective against | 11-12-2009 |
| 20090281293 | PROCESSES FOR THE PREPARATION OF 2 FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES - The present invention relates to processes and intermediates for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (X-c): | 11-12-2009 |
| 20100145035 | METHOD OF SYNTHESIZING MACROLIDE COMPOUNDS - The present invention relates to methods for synthesizing macrolide compounds which are known to have antibacterial activity, and are useful in the therapy of bacterial infections in mammals. More specifically, the invention relates to methods for synthesizing the macrolide antibiotic, gamithromycin utilizing a novel configuration of catalysts, chemical structures, and/or methods. An embodiment of the present invention may include allowing multiple chemical reactions to proceed without the isolation of chemical intermediates. Thus, multiple reactions may occur in one reaction vessel allowing for a considerable decrease in the cycle-time. The present invention also provides a novel method for inhibiting degradation while isolating a structure of a pharmaceutical composition. | 06-10-2010 |
| 20110184158 | HYDRATES OF ERYTHROMYCIN SALTS, PREPARATION AND USE THEREOF - The present invention relates to a macrolide derivative as well as preparation and use thereof. The macrolide derivative of the present invention, i.e., a hydrate of erythromycin salts, has a molecular formula of C | 07-28-2011 |
| 20110237784 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS - A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even | 09-29-2011 |
| 20130066056 | PROCESS FOR PREPARING TRIAZOLE-CONTAINING KETOLIDE ANTIBIOTICS - The invention described herein pertains to processes for the preparation of macrolide antibacterial agents. In particular, the invention pertains to processes for preparing macrolides and ketolides from erythromycin A. | 03-14-2013 |
| 20130197204 | NOVEL PROCESS FOR THE PREPARATION OF 9-DEOXO-9A-AZA-9A-HOMOERYTHROMYCIN A, MODIFIED IN THE C-44" OF THE CLADINOSE RING BY AN EPOXIDE GROUP - The present invention concerns a process for the preparation of the compound of formula | 08-01-2013 |
